Kite, A Gilead Company

This study aims to see if a new personalized cell therapy, called anitocabtagene autoleucel, works better than current standard treatments for people with multiple myeloma that has come back or stopped responding to prior therapies. It will involve about 450 participants whose ca…

This program provides access to a specialized immune cell therapy (CAR-T) for patients with certain lymphomas when their manufactured treatment doesn't meet regular commercial standards but still meets safety requirements for clinical use. It's designed for patients who cannot un…

This study is testing two new personalized cell therapies, KITE-363 and KITE-753, for people with B-cell lymphoma that has come back or hasn't responded to standard treatments. The main goals are to find a safe dose and see how well these therapies can shrink tumors. Researchers …

This study compares a personalized immune cell therapy (CAR-T) against standard chemotherapy as the first treatment for people with high-risk, aggressive lymphoma. The trial will enroll 300 participants who have just started treatment to see if CAR-T therapy can better control th…

This is a first-in-human study to test the safety of a new, one-time gene therapy called INT2104 for adults with B-cell blood cancers that have returned or not responded to prior treatments. The therapy is designed to instruct the body's own immune cells to find and fight cancer …